查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614194

內分泌藥物市場：依治療領域、通路分類 - 全球預測 2025-2030 年

Endocrinology Drugs Market by Therapy Area (Diabetes Drugs, Human Growth Hormone, Thyroid Hormone Disorders), Distribution Channel (Hospital pharmacies, Online pharmacies, Retail pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年內分泌藥物市值為327.8億美元，預計2024年將達到350.5億美元，複合年成長率為7.34%，到2030年將達到538.5億美元。

內分泌藥物市場包括治療與內分泌系統相關的疾病的藥物，例如糖尿病、甲狀腺疾病和荷爾蒙失衡。受人口老化、肥胖率上升和生活方式改變等因素影響，這些疾病在全球日益流行，推動了對內分泌藥物的需求。這些藥物可應用於荷爾蒙補充療法、血糖調節、代謝疾病管理等，為醫院、診所和個別患者等最終用戶提供服務。市場成長主要是由生物技術、個人化醫療的進步以及創新藥物輸送系統的不斷採用所推動的。新的發展機會包括開發針對特定荷爾蒙途徑的新型化合物以及提高患者對數位健康解決方案的依從性。然而，市場面臨高昂的研發成本、嚴格的法律規範以及與荷爾蒙療法相關的潛在副作用等限制，這可能會阻礙成長。還有其他問題，例如與學名藥的競爭以及由於成本限制而在發展中地區使用的限制。有前景的創新領域包括探索非侵入性輸送系統、最佳化生物相似藥以及利用人工智慧獲得精準醫學見解。此外，製藥公司和研究機構之間的合作可以促進荷爾蒙相關病理學的新發現。在一個以技術快速進步和不斷變化的醫療保健需求為特徵的市場中，相關人員需要保持資訊靈通和敏捷，強調必須採取適應性策略來滿足消費者和監管機構的需求。公司應優先考慮解決廣泛的未滿足臨床需求的研究階段投資，並探索成分和技術許可合作夥伴關係以加快上市時間。競爭格局凸顯了策略併購的重要性，這使得企業能夠擴大產品系列和區域格局。總之，對臨床試驗管道和新興法規的持續監控對於抓住內分泌藥物市場的機會和克服挑戰至關重要。

主要市場統計
基準年[2023] 327.8億美元
預計年份 [2024] 350.5億美元
預測年份 [2030] 538.5億美元
複合年成長率（%） 7.34%

市場動態：快速發展的內分泌藥物市場的關鍵市場洞察

供需的動態交互作用正在改變內分泌藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 內分泌疾病盛行率增加
    • 提高對內分泌疾病及其管理的認知
    • 人口老化的增加和生活方式的改變導致內分泌疾病的增加
  • 市場限制因素
    • 內分泌藥物研發高成本
  • 市場機會
    • 日益關注個人化醫療和標靶治療
    • 生物技術的進步促進新治療方法的開發
  • 市場挑戰
    • 藥品核准嚴格監理要求

波特五力：駕馭內分泌藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解內分泌藥物市場的外部影響

外部宏觀環境因素對內分泌藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解內分泌藥物市場競爭狀況

對內分泌藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣內分泌藥物市場供應商的績效評估

FPNV 定位矩陣是評估內分泌藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃內分泌藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，內分泌藥物市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 內分泌疾病盛行率增加
      • 提高對內分泌疾病及其管理的認知
      • 人口老化和生活方式的改變導致內分泌疾病的增加。
    • 抑制因素
      • 內分泌藥物的研發成本較高。
    • 機會
      • 日益關注個人化醫療和標靶治療
      • 生物技術的進步促進新治療方法的開發
    • 任務
      • 藥品核准嚴格監理要求
  • 市場區隔分析
    • 治療領域：隨著全球糖尿病盛行率的增加，內分泌藥物的研發正在加速。
    • 通路：由於送貨上門的便利性，網路藥局變得越來越重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療領域分類的內分泌藥物市場

  • 糖尿病藥物
  • 人體生長荷爾蒙
  • 甲狀腺激素失調

第7章 內分泌藥物市場：依分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第8章北美和南美內分泌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區內分泌藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲內分泌藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Alexion 透過收購 Amorit Pharma 加強罕見內分泌產品組合
    • 禮來公司 (Eli Lilly) 的 Munjaro 將在印度上市
    • 諾和諾德收購不變鋼 Pharma 以擴大肥胖和糖尿病治療產品組合
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Ascendis Pharma AS
  • AstraZeneca PLC
  • Bayer AG
  • Beta Cell NV
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International PLC
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Hanmi Pharm Co., Ltd.
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • MacroGenics, Inc.
  • MannKind Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals
  • Pfizer Inc.
  • Precigen, Inc.
  • Sanofi SA
  • Shenzhen Microchip Biotechnology Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-D1342F184FD3

The Endocrinology Drugs Market was valued at USD 32.78 billion in 2023, expected to reach USD 35.05 billion in 2024, and is projected to grow at a CAGR of 7.34%, to USD 53.85 billion by 2030.

The endocrinology drugs market encompasses pharmaceuticals designed to treat disorders related to the endocrine system, including diabetes, thyroid diseases, and hormonal imbalances. The necessity for endocrinology drugs is driven by the increasing prevalence of these conditions globally, influenced by factors such as aging populations, rising obesity rates, and lifestyle changes. These drugs are applied in hormone replacement therapies, glucose regulation, and metabolic disease management, serving end-users like hospitals, clinics, and individual patients. Market growth is significantly driven by advancements in biotechnology, personalized medicine, and the increasing adoption of innovative drug delivery systems. Emerging opportunities include the development of novel compounds targeting specific hormone pathways and enhancing patient compliance through digital health solutions. However, the market faces limitations such as high R&D costs, stringent regulatory frameworks, and potential side effects associated with hormonal therapies that may hinder growth. Challenges also include competition from generic drugs and limited accessibility in developing regions due to cost constraints. Innovation areas with promising potential include researching non-invasive delivery systems, optimizing biosimilars, and leveraging artificial intelligence for precision medicine insights. Moreover, collaborations between pharmaceutical companies and research institutions can foster new discoveries in hormone-related pathologies. The market, characterized by rapid technological advancements and evolving healthcare demands, requires stakeholders to stay informed and agile, emphasizing adaptive strategies to address both consumer and regulatory needs. Companies should prioritize investment in research phases that address prevalent unmet clinical needs and explore partnerships for ingredient or technology licensing to expedite time-to-market. The competitive landscape underscores the importance of strategic mergers and acquisitions, enabling firms to expand product portfolios and geographic reach. In conclusion, continuous monitoring of clinical trial pipelines and emerging regulations will be crucial for seizing opportunities and navigating challenges in the endocrinology drugs market.

KEY MARKET STATISTICS
Base Year [2023] USD 32.78 billion
Estimated Year [2024] USD 35.05 billion
Forecast Year [2030] USD 53.85 billion
CAGR (%) 7.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endocrinology Drugs Market

The Endocrinology Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of endocrine disorders
    • Growing awareness about endocrine disorders and their management
    • Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
  • Market Restraints
    • High cost associated with research and development of endocrinology drugs
  • Market Opportunities
    • Increasing focus on personalized medicine and targeted therapies
    • Advancements in biotechnology for the development of novel therapeutic options
  • Market Challenges
    • Stringent regulatory requirements for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Endocrinology Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endocrinology Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endocrinology Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endocrinology Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endocrinology Drugs Market

A detailed market share analysis in the Endocrinology Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endocrinology Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endocrinology Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endocrinology Drugs Market

A strategic analysis of the Endocrinology Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endocrinology Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ascendis Pharma AS, AstraZeneca PLC, Bayer AG, Beta Cell NV, Biocon Limited, Eli Lilly and Company, Endo International PLC, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Hanmi Pharm Co., Ltd., Ipsen Pharma, Johnson & Johnson Services, Inc., MacroGenics, Inc., MannKind Corporation, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals, Pfizer Inc., Precigen, Inc., Sanofi S.A., Shenzhen Microchip Biotechnology Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endocrinology Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Area, market is studied across Diabetes Drugs, Human Growth Hormone, and Thyroid Hormone Disorders.
  • Based on Distribution Channel, market is studied across Hospital pharmacies, Online pharmacies, and Retail pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of endocrine disorders
      • 5.1.1.2. Growing awareness about endocrine disorders and their management
      • 5.1.1.3. Growing aging population and lifestyle changes contributing to the rise in endocrine disorders.
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with research and development of endocrinology drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing focus on personalized medicine and targeted therapies
      • 5.1.3.2. Advancements in biotechnology for the development of novel therapeutic options
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for drug approval
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Area: Growing prevalence of diabetes across the globe accelerating research & development of endocrinology drugs
    • 5.2.2. Distribution Channel: Increasing significance of online pharmacies due to ease of home delivery
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endocrinology Drugs Market, by Therapy Area

  • 6.1. Introduction
  • 6.2. Diabetes Drugs
  • 6.3. Human Growth Hormone
  • 6.4. Thyroid Hormone Disorders

7. Endocrinology Drugs Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital pharmacies
  • 7.3. Online pharmacies
  • 7.4. Retail pharmacies

8. Americas Endocrinology Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Endocrinology Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Endocrinology Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Alexion to Bolster Rare Endocrinology Portfolio with Amolyt Pharma Acquisition
    • 11.3.2. Anticipated Launch of Eli Lilly's Mounjaro in India
    • 11.3.3. Novo Nordisk Acquires Inversago Pharma to Expand Obesity and Diabetes Treatment Portfolio
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Ascendis Pharma AS
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Beta Cell NV
  • 7. Biocon Limited
  • 8. Eli Lilly and Company
  • 9. Endo International PLC
  • 10. F. Hoffmann-La Roche Ltd.
  • 11. GlaxoSmithKline PLC
  • 12. Hanmi Pharm Co., Ltd.
  • 13. Ipsen Pharma
  • 14. Johnson & Johnson Services, Inc.
  • 15. MacroGenics, Inc.
  • 16. MannKind Corporation
  • 17. Merck & Co., Inc.
  • 18. Novartis AG
  • 19. Novo Nordisk A/S
  • 20. Oramed Pharmaceuticals
  • 21. Pfizer Inc.
  • 22. Precigen, Inc.
  • 23. Sanofi S.A.
  • 24. Shenzhen Microchip Biotechnology Co., Ltd.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ENDOCRINOLOGY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOCRINOLOGY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOCRINOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOCRINOLOGY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DIABETES DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HUMAN GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THYROID HORMONE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ENDOCRINOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ENDOCRINOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. ENDOCRINOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023